Imperial College London

Dr. Elita Jauneikaite

Faculty of MedicineSchool of Public Health

Advanced Research Fellow







UG5Norfolk PlaceSt Mary's Campus





Dr Elita Jauneikaite's research focuses on evolution, transmission and antimicrobial resistance of vaccine preventable and healthcare associated bacterial infections. Elita leads a research programme in bacterial pathogenesis, global trends in vaccine preventable infection and antibiotic resistance using bacterial genomics, bioinformatics and molecular biology techniques. Most important part of her research is to work together with multidisciplinary teams to combine all available information for the particular strains of the pathogen, such as clinical, large scale epidemiology, genetics of the pathogen and microbiological findings in the laboratory, to really understand all aspects that are at play when pathogens cause infections. Elita's main research concentrates on investigating the disease-causing Group B Streptococcus (GBS), where she is using whole genome sequencing and bioinformatic analyses to inform on evolution, transmission patterns and antimicrobial resistance patterns of this pathogen. Elita also leads genomics work on other bacterial pathogens including E. coli, K. pneumoniae, methicillin-susceptible S. aureus, S. argenteus, S. pyogenes, S. pneumoniae and C. difficile

Elita is an Imperial College Research Fellow in Bacterial Genomics and Epidemiology at the Department of Infectious Disease Epidemiology and Research Lead for Priority Pathogens theme in the National Institute of Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance. The HPRU is a partnership between Imperial College London, Public Health England, Cambridge University, Warwick University and Imperial College Health Partners. The Unit was funded, along with 14 others in priority areas from immunisation to radiation hazards, to bring Universities to work in partnership with Public Health England to support excellent health protection research relevant to the needs of Public Health England. It commenced 01 April 2020 for a 5 year period and builds on the legacy of the previous HPRU which ran from 01 April 2014 -31 March 2020.

Elita completed her PhD in 2014 investigating the prevalence of serotypes and genotypes of disease-causing Streptococcus pneumoniae isolates in Singapore over the last 15 years. Elita used 1760 pneumococcal whole genome sequences to investigate the structure of this pneumococcal population in relation to the epidemiological data available and pneumococcal vaccine implementation in Singapore. This was achieved with a collaboration between four major hospitals in Singapore, Genome Institute of Singapore and University of Southampton.



Watson O, Alhaffar M, Mehchy Z, et al., 2021, Leveraging community mortality indicators to infer COVID-19 mortality and transmission dynamics in Damascus, Syria, Nature Communications, Vol:12, ISSN:2041-1723, Pages:1-10

Ragonnet-Cronin M, Boyd O, Geidelberg L, et al., 2021, Genetic evidence for the association between COVID-19 epidemic severity and timing of non-pharmaceutical interventions, Nature Communications, Vol:12, ISSN:2041-1723, Pages:1-7

Myall A, Peach RL, Wan Y, et al., 2021, Characterising contact in disease outbreaks via a network model of spatial-temporal proximity

Pi L, Expert P, Clarke JM, et al., 2021, Electronic health record enabled track and trace in an urban hospital network: implications for infection prevention and control

Boonyasiri A, Jauneikaite E, Brinkac LM, et al., 2021, Genomic and clinical characterisation of multidrug-resistant carbapenemase-producing ST231 and ST16 Klebsiella pneumoniae isolates colonising patients at Siriraj hospital, Bangkok, Thailand from 2015 to 2017., Bmc Infectious Diseases, Vol:21, ISSN:1471-2334, Pages:1-11

More Publications